[EN] TANK-BINDING KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE KINASES SE LIANT À TANK
申请人:GILEAD SCIENCES INC
公开号:WO2015187684A1
公开(公告)日:2015-12-10
Compounds having the following formula (I) and methods of their use and preparation are disclosed:
揭示了具有以下化学式(I)的化合物及其使用和制备方法。
INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
申请人:Dumas Jacques
公开号:US20120046290A1
公开(公告)日:2012-02-23
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
Cyclometalated complexes are an important class of (pre)catalysts in many reactions including hydride transfer. The ring size of such complexes could therefore be a relevant aspect to consider while modulating their catalyticactivity. However, any correlation between the cyclometalating ring size and the catalyticactivity should be drawn by careful assessment of the pertinent geometrical parameters, and overall
[EN] 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER<br/>[FR] 2-ACYLAMINOTHIAZOLES POUR LE TRAITEMENT DU CANCER
申请人:UNIV MILANO BICOCCA
公开号:WO2015001024A1
公开(公告)日:2015-01-08
The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.